Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Part of paid clinical trials in Glendale, California.
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study ID
- NCT06480383
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Generalized Anxiety Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ITI-1284 10 mg — DRUGITI-1284 10 mg tablet, taken once daily, sublingual administration.
- ITI-1284 20 mg — DRUGITI-1284 20 mg tablet, taken once daily, sublingual administration.
- Placebo — DRUGMatching placebo tablet, taken once daily, sublingual administration
Study Details
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Key Dates
- First listed
- Jun 28, 2024
- Start date
- Aug 5, 2024
- Status verified
- Aug 2026
- Primary completion
- Mar 16, 2027
- Completion
- Mar 23, 2027
Study Design
- Enrollment
- 705 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: ITI-1284 10 mg
- Experimental: ITI-1284 20 mg
- Placebo Comparator: Placebo
Primary Outcome Measure
Hamilton Anxiety Rating Scale (HAM-A) [ Time Frame: Week 6 ]
Central Contacts
- Study Contact844-434-4210
Locations (25)
Find similar trials in Glendale, CA
Related Studies
- Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)Recruiting · University of California, Los Angeles · Los Angeles, California
- Brief Smartphone Treatment StudyRecruiting · Penn State University · University Park, Pennsylvania
- Respiratory Training in the Treatment of Transdiagnostic Pathological AnxietyRecruiting · University of Texas at Austin · Austin, Texas
- CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based TherapyRecruiting · Jasper A. Smits · Boston, Massachusetts